Once-Daily Administration of Budesonide Turbuhaler® was as Effective as Twice-Daily Treatment in Patients with Mild to Moderate Persistent Asthma

Abstract

In a double-blind, randomized, placebo-controlled trial, 288 patients with mild to moderate persistent asthma currently on inhaled glucocorticosteroids (GCSs) were treated with budesonide Turbuhaler®, 200 µg once every night (q.n.), 100 µg twice-daily (b.i.d.), or placebo b.i.d. After 12 weeks, morning peak expiratory flow (PEF) increased in both groups treated with budesonide but decreased in placebo-treated patients. Symptom scores and bronchodilator use were significantly reduced in both groups receiving active treatment (p = 0.023–0.0001) compared with patients treated with placebo. There was no significant difference in outcome measurements between the two budesonide regimens. Thus, patients with mild to moderate persistent asthma receiving b.i.d. treatment with inhaled GCSs can usually be switched to budesonide Turbuhaler®, 200 µg, q.n. without loss of asthma control.

• Asthma
• Budesonide
• Beclomethasone dipropionate
• Inhaled glucocorticosteroids
• Nocturnal steroid dosing